Canakinumab for the treatment of autoinflammatory recurrent fever syndromes
De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, Kone-Paut I, Lachmann HJ, Ozen S, et al.
N Engl J Med · 2018
Grade ARCT
Key Findings
- ●CLUSTER phase III trial: canakinumab vs placebo in FMF, MKD, and TRAPS
- ●TRAPS: 45% complete response with canakinumab vs 8% placebo (p=0.006)
- ●Effective in controlling and preventing flares
Referenced in (1 disease)
ID: pmid-29768139DOI: 10.1056/NEJMoa1706314PMID: 29768139